Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil for Falls in Parkinson's Disease
NCT00912808Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2005
- Primary completion
- Feb 2009
- Sponsor
- Oregon Health & Science University
- Modality
- Small Molecules
- Drugs
- donepezil
- Conditions
- Parkinson's disease (PD)
01
Overview
Phase 2, randomised, double-blind trial of donepezil in Parkinson's disease (PD) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Fall Frequency Per Day at 6 weeks. Started Oct 2005; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Donepezil -> Placebo
Subjects receive Donepezil in Period 1 and Placebo in Period 2
Placebo -> Donepezil
Subjects receive Placebo in Period 1 and Donepezil in Period 2
03
Who it enrols
Adults >21 with Parkinson's disease treated with dopaminergic medication for at least 1 year, who are ambulatory but report frequent falls (>2/week). Excludes those with dementia (MMSE < 25), non-CNS causes of falls, or use of Warfarin or cholinergic/anticholinergic meds.
04
Endpoints
Primary
Fall Frequency Per Day
Secondary
Frequency of Near Falls Per Day
Beyond the preview
Go deeper on NCT00912808.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912808.